CAMBRIDGE, UKâ€”A new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New England Journal of Medicine that circulating tumour DNA is a more powerful marker of breast cancer progression than using blood tests for cancer cells or antigens, and raises the possibility of screening the effectiveness of drugs in days rather than months needed to wait for a change in radiological appearance.
You may also like...
“Promising Activity” Of Cetuximab In Patients With Advanced Biliary Cancer 8 Aug, 2009 Geriatric Assessment Improved Outcomes for Older Patients with Cancer 11 Jul, 2018 Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 Audio Journal of Oncology in Advance – April 15th, 2007 – Bisphosphonates Recommended for Lung Cancer Bone Metastases 15 Apr, 2007
- Previous story Circulating free tumour DNA test could guide breast cancer therapy
- Next story Two-step immunotherapy brings promise in advanced ovarian cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014